TY - JOUR
T1 - Quantifying the role of PSA screening in the US prostate cancer mortality decline
AU - Etzioni, Ruth
AU - Tsodikov, Alex
AU - Mariotto, Angela
AU - Szabo, Aniko
AU - Falcon, Seth
AU - Wegelin, Jake
AU - Ditommaso, Dante
AU - Karnofski, Kent
AU - Gulati, Roman
AU - Penson, David F.
AU - Feuer, Eric
N1 - Funding Information:
Acknowledgment This research was supported by U01 CA88160, a co-operative agreement between the National Cancer Institute and the collaborating institutions. This funding mechanism explicitly requires collaboration between the awardees and investigators at the funding source, who provide guidance to the awardees regarding goals and deliverables of the funded projects. In the work presented here, the collaborating institutions were responsible for model development, and investigators at the funding source were responsible for overall guidance and for providing key model inputs, such as other-cause mortality and PSA dissemination trends. These inputs were used by both models for standardization and comparability purposes.
PY - 2008/3
Y1 - 2008/3
N2 - Objective: To quantify the plausible contribution of prostate-specific antigen (PSA) screening to the nearly 30% decline in the US prostate cancer mortality rate observed during the 1990s. Methods: Two mathematical modeling teams of the US National Cancer Institute's Cancer Intervention and Surveillance Modeling Network independently projected disease mortality in the absence and presence of PSA screening. Both teams relied on Surveillance, Epidemiology, and End Results (SEER) registry data for disease incidence, used common estimates of PSA screening rates, and assumed that screening, by shifting disease from distant to local-regional clinical stage, confers a corresponding improvement in disease-specific survival. Results: The teams projected similar mortality increases in the absence of screening and decreases in the presence of screening after 1985. By 2000, the models projected that 45% (Fred Hutchinson Cancer Research Center) to 70% (University of Michigan) of the observed decline in prostate cancer mortality could be plausibly attributed to the stage shift induced by screening. Conclusions: PSA screening may account for much, but not all, of the observed drop in prostate cancer mortality. Other factors, such as changing treatment practices, may also have played a role in improving prostate cancer outcomes.
AB - Objective: To quantify the plausible contribution of prostate-specific antigen (PSA) screening to the nearly 30% decline in the US prostate cancer mortality rate observed during the 1990s. Methods: Two mathematical modeling teams of the US National Cancer Institute's Cancer Intervention and Surveillance Modeling Network independently projected disease mortality in the absence and presence of PSA screening. Both teams relied on Surveillance, Epidemiology, and End Results (SEER) registry data for disease incidence, used common estimates of PSA screening rates, and assumed that screening, by shifting disease from distant to local-regional clinical stage, confers a corresponding improvement in disease-specific survival. Results: The teams projected similar mortality increases in the absence of screening and decreases in the presence of screening after 1985. By 2000, the models projected that 45% (Fred Hutchinson Cancer Research Center) to 70% (University of Michigan) of the observed decline in prostate cancer mortality could be plausibly attributed to the stage shift induced by screening. Conclusions: PSA screening may account for much, but not all, of the observed drop in prostate cancer mortality. Other factors, such as changing treatment practices, may also have played a role in improving prostate cancer outcomes.
KW - Computer simulation
KW - Prostate cancer
KW - Prostate-specific antigen
KW - Public health
UR - http://www.scopus.com/inward/record.url?scp=38949085322&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38949085322&partnerID=8YFLogxK
U2 - 10.1007/s10552-007-9083-8
DO - 10.1007/s10552-007-9083-8
M3 - Article
C2 - 18027095
AN - SCOPUS:38949085322
SN - 0957-5243
VL - 19
SP - 175
EP - 181
JO - Cancer Causes and Control
JF - Cancer Causes and Control
IS - 2
ER -